This is a preview of subscription content, log in via an institution to check access.
References
Guerrini, M. et al. Nat. Biotechnol. 26, 669–675 (2008).
Guerrini, M. et al. Proc. Natl. Acad. Sci. USA 106, 16956–16961 (2009).
Kishimoto, T.K. et al. N. Engl. J. Med. 358, 2457–2467 (2008).
Hovingh, P., Piepkorn, M. & Linker, A. Biochem. J. 237, 573–581 (1986).
Acostamadiedo, J.M., Iyer, U.G. & Owen, J. Expert Opin. Pharmacother. 1, 803–814 (2000).
Anonymous. Danaparoid. http://en.wikipedia.org/wiki/Orgaran (accessed 17 February 2010).
Frazier, S.B., Roodhouse, K., Hourcade, D.E. & Zhang, L. Open Glycosci. 1, 31–39 (2008).
Studelska, D.R., Giljum, K., McDowell, L.M. & Zhang, L. Glycobiology 16, 65–72 (2006).
Volpi, N., Maccari, F. & Linhardt, R.J. Anal. Biochem. 388, 140–145 (2009).
Zhang, Z. et al. J. Pharm. Sci. 98, 4017–4026 (2009).
Liu, H., Zhang, Z. & Linhardt, R.J. Nat. Prod. Rep. 26, 313–321 (2009).
Li, F. et al. Glycoconj. J. 25, 603–610 (2008).
Fareed, J. et al. Int. Angiol. 27, 457–461 (2008).
Volpi, N. J. Chromatogr. B Biomed. Appl. 685, 27–34 (1996).
Warda, M., Gouda, E.M., Toida, T., Chi, L. & Linhardt, R.J. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136, 357–365 (2003).
Pan, J. et al. Glyobiol. Insights 2, 1–12 (2010).
Maruyama, T., Toida, T., Imanari, T., Yu, G. & Linhardt, R.J. Carbohydr. Res. 306, 35–43 (1998).
Toida, T. et al. Int. J. Biol. Macromol. 26, 233–241 (1999).
Blossom, D.B. et al. N. Engl. J. Med. 359, 2674–2684 (2008).
Ahmad, S. Front. Biosci. 12, 3312–3320 (2007).
Acknowledgements
The authors would like to thank H. Ye and J. Reepmeyer of the FDA for purification of heparin contaminants and capillary electrophoresis analysis of heparin samples. The authors would like to thank A. d'Avignon of Washington University for the analysis of samples by NMR. The authors also thank J. Esko, E. Conrad, S. Kornfeld, J. Baenziger and D. Tollefsen for their suggestions, comments and critiques of the manuscript. L.Z. thanks E. Unanue, S. Santoro, J. Ladenson and N. Brown for their support in establishing a GAG structure/function laboratory at Washington University. L.Z. thanks J. Metz for critical reading of the original manuscript. This work is supported in part by US National Institutes of Health grant R01GM069968 to L.Z. and a St. Louis Children's Discovery Institute Research Fund to L.Z.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figures, Tables and Methods
Supplementary Figures 1–5, Supplementary Table 1, and Supplementary Materials and Methods (PDF 720 kb)
Rights and permissions
About this article
Cite this article
Pan, J., Qian, Y., Zhou, X. et al. Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat Biotechnol 28, 203–207 (2010). https://doi.org/10.1038/nbt0310-203
Issue Date:
DOI: https://doi.org/10.1038/nbt0310-203
- Springer Nature America, Inc.
This article is cited by
-
Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician
Journal of Thrombosis and Thrombolysis (2012)
-
Simple fluorescence assay for quantification of OSCS in heparin
Analytical and Bioanalytical Chemistry (2011)
-
Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins
Analytical and Bioanalytical Chemistry (2011)
-
Characterization of currently marketed heparin products: key tests for quality assurance
Analytical and Bioanalytical Chemistry (2011)
-
Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples
Analytical and Bioanalytical Chemistry (2011)